DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Olaparibis the generic ingredient in one branded drug marketed by Astrazeneca Pharms and is included in two NDAs. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Olaparib has two hundred and seventy-nine patent family members in fifty countries.
There are three drug master file entries for olaparib. One supplier is listed for this compound.
Recent Clinical Trials for olaparib
Identify potential brand extensions & 505(b)(2) entrants
|Ruijin Hospital||Phase 1/Phase 2|
|Baptist Health South Florida||Phase 2|
|Florida Department of Health||Phase 2|
Pharmacology for olaparib
|Drug Class||Poly(ADP-Ribose) Polymerase Inhibitor |
|Mechanism of Action||Poly(ADP-Ribose) Polymerase Inhibitors |
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Astrazeneca Pharms||LYNPARZA||olaparib||CAPSULE;ORAL||206162-001||Dec 19, 2014||RX||Yes||Yes||Start Trial||Start Trial||Start Trial|
|Astrazeneca Pharms||LYNPARZA||olaparib||TABLET;ORAL||208558-002||Aug 17, 2017||RX||Yes||Yes||Start Trial||Start Trial||Start Trial|
|Astrazeneca Pharms||LYNPARZA||olaparib||TABLET;ORAL||208558-001||Aug 17, 2017||RX||Yes||No||Start Trial||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|
|Patent Number||Supplementary Protection Certificate||SPC Country||SPC Expiration||SPC Description|
|1633724||1590019-4||Sweden||Start Trial||PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REG. NO/DATE: EU/1/14/959 20141218|
|2346495||LUC00091||Luxembourg||Start Trial||PRODUCT NAME: OLAPARIB AMORPHE OU UN DE SES SELS OU UN DES SES SOLVATES DANS UNE DISPERSION SOLIDE; AUTHORISATION NUMBER AND DATE: EU/1/14/959 20180515|
|1633724||213 50005-2015||Slovakia||Start Trial||PRODUCT NAME: OLAPARIB; REGISTRATION NO/DATE: EU/1/14/959 20141218|
|>Patent Number||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration||>SPC Description|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.